IMCYSE SA

Their core work

IMCYSE SA is a Belgian biotech SME focused on immunological approaches to type 1 diabetes — specifically on understanding beta-cell destruction, identifying disease biomarkers, and developing novel therapeutic interventions. They work within large European clinical trial networks, contributing specialist expertise in immunology and disease mechanisms to translational research pipelines. Their work spans from early detection and biobanking to mechanistic studies of how the immune system attacks insulin-producing cells, with the applied goal of preventing or reversing the disease. As a private company rather than a university or hospital, they bring a product-development orientation to consortia that are otherwise dominated by academic and clinical partners.

What they specialise in

How they've shifted over time

In their first project (INNODIA, 2015), IMCYSE's contribution was oriented around the foundational layer of clinical research: building biobanks, establishing clinical sample networks, defining biomarkers, and developing integrative data-analysis methods — the infrastructure needed before any therapeutic hypothesis can be tested. By INNODIA HARVEST (2020), the emphasis shifted decisively toward mechanisms and intervention: beta-cell biology, microbiome interactions, immunological disease drivers, and novel therapeutics, alongside more sophisticated trial methodology including master-protocols and patient voice. The trajectory is consistent with a biotech SME that joined as a specialist contributor to a network-building phase and is now contributing directly to the therapeutic development phase of the same platform.

IMCYSE is moving from upstream research infrastructure toward therapeutic development and clinical application, suggesting they are maturing toward product-stage activities in T1D immunotherapy.

How they like to work

IMCYSE has never led a project — both participations are as consortium partner within the INNODIA family, which is among the largest European T1D research initiatives. This suggests they function as a specialist contributor that is valued for a defined capability rather than for project management or coordination. With 43 unique partners across 16 countries accumulated over just two projects, they clearly operate comfortably within very large, multi-stakeholder consortia rather than small bilateral partnerships.

IMCYSE has built connections with 43 distinct consortium partners across 16 countries through just two projects, both within the INNODIA clinical network — one of Europe's broadest T1D research collaborations. Their network is European in scope and heavily weighted toward clinical and academic institutions involved in autoimmune disease research.

What sets them apart

IMCYSE is a rare private-sector SME embedded at the heart of a large publicly-funded clinical research network, giving them early access to biomarker data, patient cohorts, and clinical trial infrastructure that most pharma companies would pay significant sums to access. Their location in Sart Tilman (Liège), proximity to major Belgian academic medical centers, and continuous participation in the INNODIA platform from 2015 to 2024 suggests deep institutional ties that make them a credible bridge between academic T1D research and commercial therapeutic development. For a consortium builder, they offer the unusual combination of SME agility and embedded clinical network access.

Highlights from their portfolio

• INNODIA
  An 8-year flagship initiative (2015–2023) that established the pan-European infrastructure for T1D clinical research — biobanks, sample networks, and integrated data analysis — making it one of the most ambitious translational diabetes projects in H2020.
• INNODIA HARVEST
  The follow-on project (2020–2024) that built on INNODIA's infrastructure to advance toward therapeutics, introducing master-protocol trial design and patient-voice integration — signaling the transition from research platform to clinical intervention.